Stocks
Heron Therapeutics Financial Statements (HRTX) |
||||||||||
| Heron Therapeuticssmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 02.03.2020 | 24.02.2021 | 28.02.2022 | 29.03.2023 | 12.03.2024 | 06.08.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 146.0 | 88.6 | 86.3 | 107.7 | 127.0 | 136.4 | |||
| Operating Income, bln rub | -210.7 | -228.2 | -217.8 | -174.7 | -110.6 | -46.4 | ||||
| EBITDA, bln rub | ? | -208.7 | -228.2 | -217.8 | -174.7 | -107.7 | -43.6 | |||
| Net profit, bln rub | ? | -204.7 | -224.4 | -217.7 | -134.5 | -110.6 | -48.1 | |||
| OCF, bln rub | ? | -124.6 | -184.8 | -203.4 | -146.9 | -58.8 | -20.8 | |||
| CAPEX, bln rub | ? | 7.15 | 6.81 | 3.02 | 1.83 | 1.55 | 1.68 | |||
| FCF, bln rub | ? | -131.7 | -191.6 | -206.4 | -148.7 | -60.3 | -22.5 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 295.0 | 280.6 | 258.2 | 227.5 | 172.6 | 135.7 | ||||
| Cost of production, bln rub | 61.6 | 36.2 | 46.0 | 54.9 | 65.1 | 47.1 | ||||
| R&D, bln rub | 167.4 | 174.5 | 130.8 | 107.5 | 55.9 | 33.5 | ||||
| Interest expenses, bln rub | 1.47 | 1.90 | 2.41 | 2.47 | 3.87 | 2.73 | ||||
| Assets, bln rub | 512.8 | 353.6 | 305.7 | 251.0 | 222.5 | 218.1 | ||||
| Net Assets, bln rub | ? | 403.8 | 236.5 | 77.6 | 13.6 | -34.0 | -37.9 | |||
| Debt, bln rub | 19.8 | 24.6 | 159.5 | 157.5 | 179.6 | 178.7 | ||||
| Cash, bln rub | 391.0 | 208.5 | 157.6 | 84.9 | 80.4 | 67.3 | ||||
| Net debt, bln rub | -371.2 | -183.9 | 1.92 | 72.6 | 99.2 | 111.4 | ||||
| Ordinary share price, rub | 23.5 | 21.2 | 9.13 | 2.50 | 1.70 | 0.670 | ||||
| Number of ordinary shares, mln | 81.8 | 90.8 | 98.5 | 108.9 | 138.1 | 152.3 | ||||
| Market cap, bln rub | 1 922 | 1 921 | 899 | 272 | 235 | 102 | ||||
| EV, bln rub | ? | 1 551 | 1 737 | 901 | 345 | 334 | 213 | |||
| Book value, bln rub | 404 | 236 | 78 | 14 | -34 | -38 | ||||
| EPS, rub | ? | -2.50 | -2.47 | -2.21 | -1.24 | -0.80 | -0.32 | |||
| FCF/share, rub | -1.61 | -2.11 | -2.10 | -1.37 | -0.44 | -0.15 | ||||
| BV/share, rub | 4.94 | 2.61 | 0.79 | 0.12 | -0.25 | -0.25 | ||||
| EBITDA margin, % | ? | -142.9% | -257.4% | -252.3% | -162.2% | -84.8% | -32.0% | |||
| Net margin, % | ? | -140.3% | -253.2% | -252.1% | -124.9% | -87.0% | -35.3% | |||
| FCF yield, % | ? | -6.85% | -9.97% | -23.0% | -54.6% | -25.7% | -22.1% | |||
| ROE, % | ? | -50.7% | -94.9% | -280.6% | -991.1% | 325.4% | 126.9% | |||
| ROA, % | ? | -39.9% | -63.5% | -71.2% | -53.6% | -49.7% | -22.1% | |||
| P/E | ? | -9.39 | -8.56 | -4.13 | -2.02 | -2.12 | -2.12 | |||
| P/FCF | -14.6 | -10.0 | -4.36 | -1.83 | -3.89 | -4.53 | ||||
| P/S | ? | 13.2 | 21.7 | 10.4 | 2.53 | 1.85 | 0.75 | |||
| P/BV | ? | 4.76 | 8.12 | 11.6 | 20.1 | -6.91 | -2.69 | |||
| EV/EBITDA | ? | -7.43 | -7.61 | -4.14 | -1.97 | -3.10 | -4.89 | |||
| Debt/EBITDA | 1.78 | 0.81 | -0.01 | -0.42 | -0.92 | -2.55 | ||||
| R&D/CAPEX, % | 2 340% | 2 562% | 4 329% | 5 891% | 3 618% | 1 997% | ||||
| CAPEX/Revenue, % | 4.90% | 7.69% | 3.50% | 1.69% | 1.22% | 1.23% | ||||
| Heron Therapeutics shareholders | ||||||||||
